Share information
210.50 €
+2.38 %
14/09/2026 17:35
+2.38 %
Open
High
Low
Volume
207.70 €
210.90 €
206.30 €
226,890
Latest News
09-Sep-2026
UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA[®] (certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS)
08-Sep-2026
UCB opens ‘Expressing Epilepsy’ art exhibition featuring acclaimed artists living with epilepsy
01-Sep-2026
UCB presents data at EEC 2026 highlighting continued leadership in epilepsy and developmental and epileptic encephalopathies
31-Aug-2026
Transparency notification Wellington Management Group LLP